<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701828</url>
  </required_header>
  <id_info>
    <org_study_id>201808128</org_study_id>
    <nct_id>NCT03701828</nct_id>
  </id_info>
  <brief_title>Liver Health and Metabolic Function in People With Obesity</brief_title>
  <official_title>Liver Health and Metabolic Function in People With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to determine the effect of significant weight loss on rates on hepatic
      fibrogenesis in people with obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) affects approximately 70% of those with obesity and
      if left untreated can progress to cirrhosis and liver failure. NAFLD stages progress from the
      stage of simple steatosis to steatohepatitis, and fibrosis The stage of NAFLD is currently
      best determined using histology from a liver biopsy, however this provides a static depiction
      of the state of the liver. Therefore This project aims to determine fibrogenesis in the liver
      of obese humans in vivo, before and after weight loss.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Fibrogenesis</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Rates of liver collagen synthesis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver histology</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Analysis of liver tissue morphology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma protein synthesis</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Synthesis rates of collagen-related proteins in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue inflammation</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Liver, adipose tissue, and blood immune cell content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Plasma cytokine concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue bacterial contamination</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>bacterial 16s ribosomal ribonucleic acid content will be assessed in blood and tissue samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Body composition assessed by dual-energy x-ray absorptiometry and magnetic resonance scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Urinary excretion of indigestible sugars will be assessed over 24 hours after an oral challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose histology</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Assessment of adipose tissue morphology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue gene expression</measure>
    <time_frame>Before and after ~20% weightloss, up to 6 months</time_frame>
    <description>Messenger ribonucleic acid content of adipose, liver and blood tissues will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Weight loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo weight loss surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Weight loss surgery</intervention_name>
    <description>All surgery types will be included</description>
    <arm_group_label>Weight loss</arm_group_label>
    <other_name>Sleeve gastrectomy, Roux-en-Y, biliopancreatic diversion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index â‰¥35 kg/m2

          -  Scheduled for Bariatric surgery

        Exclusion Criteria:

          -  Significant organ disfunction/disease

          -  Tobacco use

          -  Previous bariatric surgery

          -  Pregnancy

          -  Excessive alcohol use

          -  Liver disease other than NAFLD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Coordinator</last_name>
    <phone>314-362-8250</phone>
    <email>bhenk@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>314-362-8250</phone>
      <email>bhenk@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Beals</last_name>
      <phone>3143628199</phone>
      <email>bealsjw@wustl.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

